Patents Assigned to AntiCancer, Inc.
  • Patent number: 11871731
    Abstract: A transplantation method to increase the establishment rate of human tumors in immunodeficient mice. A pocket is created in the mouse and the tumor and surrounding tissues are implanted in the pocket. The pocket is left open to oxygenate the tumor and surrounding tissues.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: January 16, 2024
    Assignee: ANTICANCER, INC.
    Inventors: Robert M. Hoffman, Chihiro Hozumi
  • Publication number: 20210254040
    Abstract: A composition and method for lowing serum and plasma levels of methionine by oral administration. The composition includes a recombinant methioninase enzyme and a cofactor (pyridoxal-L-phosphate). Methods of use describe methods for treatment of cancer, including malignant melanoma, by oral administration of the methioninase composition. Methods for chronic suppressive therapy of melanoma and other cancers are described. Because reduction of plasma methionine levels is effective in treating other conditions, including diabetes and conditions associated with aging, the use of the methods described herein includes treatment of these and other conditions.
    Type: Application
    Filed: April 8, 2021
    Publication date: August 19, 2021
    Applicant: AntiCancer Inc.
    Inventors: Qinghong Han, Robert M. Hoffman
  • Patent number: 11001826
    Abstract: A composition and method for lowing serum and plasma levels of methionine by oral administration. The composition includes a recombinant methioninase enzyme and a cofactor (pyridoxal-L-phosphate). Methods of use describe methods for treatment of cancer, including malignant melanoma, by oral administration of the methioninase composition. Methods for chronic suppressive therapy of melanoma and other cancers are described. Because reduction of plasma methionine levels is effective in treating other conditions, including diabetes and conditions associated with aging, the use of the methods described herein includes treatment of these and other conditions.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: May 11, 2021
    Assignee: ANTICANCER, INC.
    Inventors: Qinghong Han, Shukuan Li, Yuying Tan, Kei Kawaguchi, Robert M. Hoffman, Sant Chawla
  • Patent number: 9539290
    Abstract: An individualized bacterial treatment of cancer is provided. The treatment includes a strain of bacteria modified by in-vivo passage through tumor grafts in experimental animals, where the modified strain exhibits enhanced cancer cell-targeting of a specific malignancy arising in a unique individual to the corresponding parent strain of bacteria. The treatment uses this modified strain for the treatment human solid-tumor malignancies by inoculating an individual with a quantity of the strain; and repeating inoculations at periodic intervals where repeated inoculations tend to progressively eliminate the solid tumor malignancy in the individual.
    Type: Grant
    Filed: December 24, 2013
    Date of Patent: January 10, 2017
    Assignee: AntiCancer Inc.
    Inventors: Ming Zhao, Fuminari Uehara
  • Patent number: 9464312
    Abstract: A composition, method and kit for performing a two-reagent enzymatic homocysteine assay, wherein a single homocysteinase enzyme and a Schiff-based conjugate of N,N-dibutyl-p-phenyldiamine (DBPDA) with pyridoxal 5?-phosphate (PLP) are used to measure total homocysteine in plasma or serum. The assay measures a chromophore reaction product of H2S and the DBPDA released from the Schiff-base conjugate in the presence of a Fe+3 containing compound. The resulting chromophore may be measured absorbance or fluorescence spectrophotometry.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: October 11, 2016
    Assignee: AntiCancer, Inc.
    Inventors: Yuying Tan, Shukuan Li
  • Patent number: 8822194
    Abstract: Bacteria that are auxotrophic for at least two amino acids found in at least one tumor are effective anti tumor treatments, labeling agents, and vaccines against infection. Improved antitumor effects can also be provided such strains by passage through an appropriate tumor model.
    Type: Grant
    Filed: June 29, 2005
    Date of Patent: September 2, 2014
    Assignee: Anticancer, Inc.
    Inventors: Ming Zhao, Meng Yang
  • Publication number: 20140205583
    Abstract: This invention relates to methods of modifying pyridoxal 5? phosphate (PLP) dependent enzymes to extend the serum half-life of the enzyme, extend the in vivo period of methionine depletion in a host, and decrease the immunogenicity of the enzyme. A preferred PLP-dependent enzyme to be modified is a methioninase, preferably a recombinant methioninase (rMETase). The invention further relates to compositions comprising a modified PLP-dependent enzyme and methods of using the same.
    Type: Application
    Filed: January 23, 2014
    Publication date: July 24, 2014
    Applicant: ANTICANCER, INC.
    Inventors: Shigeo YAGI, Zhijian YANG, Shukuan LI, Xinghua SUN, Yuying TAN
  • Publication number: 20140193801
    Abstract: A composition, method and kit for performing a two-reagent enzymatic homocysteine assay, wherein a single homocysteinase enzyme and a Schiff-based conjugate of N,N-dibutyl-p-phenyldiamine (DBPDA) with pyridoxal 5?-phosphate (PLP) are used to measure total homocysteine in plasma or serum. The assay measures a chromophore reaction product of H2S and the DBPDA released from the Schiff-base conjugate in the presence of a Fe+3 containing compound. The resulting chromophore may be measured absorbance or fluorescence spectrophotometry.
    Type: Application
    Filed: January 10, 2014
    Publication date: July 10, 2014
    Applicant: ANTICANCER, INC.
    Inventors: Yuying Tan, Shukuan Li
  • Publication number: 20140178341
    Abstract: An individualized bacterial treatment of cancer is provided. The treatment includes a strain of bacteria modified by in-vivo passage through tumor grafts in experimental animals, where the modified strain exhibits enhanced cancer cell-targeting of a specific malignancy arising in a unique individual to the corresponding parent strain of bacteria. The treatment uses this modified strain for the treatment human solid-tumor malignancies by inoculating an individual with a quantity of the strain; and repeating inoculations at periodic intervals where repeated inoculations tend to progressively eliminate the solid tumor malignancy in the individual.
    Type: Application
    Filed: December 24, 2013
    Publication date: June 26, 2014
    Applicant: ANTICANCER, INC.
    Inventors: Ming Zhao, Fuminari Uehara
  • Publication number: 20140180073
    Abstract: A portable digital imaging system for fluorescence-guided surgery is provided. The system includes a portable probe comprising a light source, a fluorescence detector, a digital signal output, a memory and a processor. The system also includes a computer in communication with the portable probe and a display. The portable probe excites a fluorescent label-containing tissue within a surgical field in response to the light source of the portable probe illuminating the fluorescent label-containing tissue. The computer displays a real-time image visualization of the surgical field on the display in response to the computer in communication with the display receiving and processing a digital signal from the digital signal output of the portable probe.
    Type: Application
    Filed: December 24, 2013
    Publication date: June 26, 2014
    Applicant: AntiCancer, Inc.
    Inventors: Yukihiko Hiroshima, Yong Zhang
  • Publication number: 20130252306
    Abstract: The present invention relates to highly conjugated proteins and methods for making such proteins. In particular, the present invention relates to methods for linking additional sites to a protein for conjugation with activated polyethylene glycol (PEG) linkers, without denaturing the protein. The invention also relates to highly conjugated proteins with decreased immunogenicity and increased circulating half-life.
    Type: Application
    Filed: May 21, 2013
    Publication date: September 26, 2013
    Applicant: ANTICANCER, INC.
    Inventors: Shukuan LI, Zhijian YANG, Xinghua SUN, Yuying TAN, Shigeo YAGI
  • Patent number: 8481318
    Abstract: Hair follicle stem cells are isolated in a method which relies on the identification of stem cells as being small, spindle, oval or round shaped nestin-expressing cells that are located in the permanent upper part of telogen hair follicles below the sebaceous glands and in the bulge area.
    Type: Grant
    Filed: January 26, 2010
    Date of Patent: July 9, 2013
    Assignee: Anticancer, Inc.
    Inventors: Lingna Li, Meng Yang
  • Patent number: 8465734
    Abstract: The present invention relates to highly conjugated proteins and methods for making such proteins. In particular, the present invention relates to methods for linking additional sites to a protein for conjugation with activated polyethylene glycol (PEG) linkers, without denaturing the protein. The invention also relates to highly conjugated proteins with decreased immunogenicity and increased circulating half-life.
    Type: Grant
    Filed: September 3, 2010
    Date of Patent: June 18, 2013
    Assignee: AntiCancer, Inc.
    Inventors: Shukuan Li, Zhijian Yang, Xinghua Sun, Yuying Tan, Shigeo Yagi
  • Publication number: 20120316321
    Abstract: A method is described to identify secreted proteins identified with stages of malignancy of cancer. The proteins are initially identified by trapping them with a fluorescent protein containing vector that can insert in any gene. The secreted proteins are initially identified by their fluorescence. Secreted proteins identifying tumors with specific degrees of malignancy are isolated to determine if they can serve as markers of cancer progression.
    Type: Application
    Filed: June 15, 2012
    Publication date: December 13, 2012
    Applicants: The United States Government as Represented by the Secretary, Dept. of Health and Human Services, AntiCancer, Inc.
    Inventors: Mingxu XU, Yuying Tan, Levy Kopelovich
  • Patent number: 8217222
    Abstract: A method is described to identify secreted proteins identified with stages of malignancy of cancer. The proteins are initially identified by trapping them with a fluorescent protein containing vector that can insert in any gene. The secreted proteins are initially identified by their fluorescence. Secreted proteins identifying tumors with specific degrees of malignancy are isolated to determine if they can serve as markers of cancer progression.
    Type: Grant
    Filed: September 29, 2006
    Date of Patent: July 10, 2012
    Assignees: Anticancer, Inc., The United States of America as represented by the Department of Health and Human Services
    Inventors: Mingxu Xu, Yuying Tan, Levy Kopelovich
  • Patent number: 8148600
    Abstract: Immunocompromised rodents that have been modified to express a fluorescent protein in substantially all tissues are described. These rodents are useful as models for gene expression, tumor progression and angiogenesis. Also provided are model systems where heterologous tissues fluorescing in a first color are transplanted into hosts that have been modified to fluoresce in substantially all tissues with a second color.
    Type: Grant
    Filed: February 9, 2004
    Date of Patent: April 3, 2012
    Assignee: Anticancer, Inc.
    Inventors: Meng Yang, Eligio Reynoso, Mingxu Xu, Ping Jiang
  • Publication number: 20100331529
    Abstract: The present invention relates to highly conjugated proteins and methods for making such proteins. In particular, the present invention relates to methods for linking additional sites to a protein for conjugation with activated polyethylene glycol (PEG) linkers, without denaturing the protein. The invention also relates to highly conjugated proteins with decreased immunogenicity and increased circulating half-life.
    Type: Application
    Filed: September 3, 2010
    Publication date: December 30, 2010
    Applicant: AntiCancer, Inc.
    Inventors: Shukuan Li, Zhijian Yang, Xinghua Sun, Yuying Tan, Shigeo Yagi
  • Patent number: 7799549
    Abstract: The present invention relates to highly conjugated proteins and methods for making such proteins. In particular, the present invention relates to methods for linking additional sites to a protein for conjugation with activated polyethylene glycol (PEG) linkers, without denaturing the protein. The invention also relates to highly conjugated proteins with decreased immunogenicity and increased circulating half-life.
    Type: Grant
    Filed: December 10, 2007
    Date of Patent: September 21, 2010
    Assignee: Anticancer, Inc.
    Inventors: Shukuan Li, Zhijian Yang, Xinghua Sun, Yuying Tan, Shigeo Yagi
  • Publication number: 20100146643
    Abstract: An animal model of angiogenesis is described. Nascent blood vessels are supported by a growth matrix comprising a growth factor. The nascent blood vessels are labeled with a fluorescent protein selectively expressed in cells forming these vessels.
    Type: Application
    Filed: September 27, 2007
    Publication date: June 10, 2010
    Applicant: ANTICANCER, INC
    Inventor: Yasuyuki Amoh
  • Publication number: 20100068148
    Abstract: A enhanced method for observing tumor progression, angiogenesis and/or metastasis in animal models in real time is described. The invention employs a skin flap over the area to be observed that can be opened and closed reversibly. The invention also permits simultaneous observation of more than one tumor by use of multiple colors.
    Type: Application
    Filed: November 19, 2009
    Publication date: March 18, 2010
    Applicant: AntiCancer, Inc.
    Inventors: Meng YANG, Eugene Baranov, Jin Wei Wang